BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lannett Company, Inc. (LCI) Announces The Signing Of A Supply Agreement With Orion Pharma


10/19/2005 5:11:57 PM

PHILADELPHIA, Oct. 27 /PRNewswire-FirstCall/ -- Lannett Company, Inc. is pleased to announce the signing of an agreement with Orion Pharma (Orion), Finland's leading drug company, for the exclusive supply of three drug products.

Under the terms of the agreement, Orion will supply Lannett with the finished products and all laboratory documentation; and Lannett will coordinate the completion of the clinical biostudies necessary to submit Abbreviated New Drug Applications (ANDAs) to the Food and Drug Administration (FDA). Once approved, Lannett has the exclusive contractual right to market and distribute the products in the United States. Since Lannett and Orion have no control over the FDA review process, they are unable to anticipate whether or when they will be able to begin commercially shipping the products.

Arthur Bedrosian, Lannett's President, said, "We are delighted to work with Orion on these projects. We have pursued opportunities with foreign and domestic manufacturers in order to expand the line of products we offer to our customers. This strategy complements our internal drug development and manufacturing by allowing us to expand our research & development initiatives to increase the number of ANDAs to be submitted to the FDA. Of course, we expect these plans to increase our future revenues and income."

Established in 1917, Orion (http://www.orion.fi/ ) has evolved into the leading pharmaceutical company in Finland. With several different business divisions, Orion has increased its world-wide presence in the pharmaceutical industry with subsidiaries in 15 countries. Orion Corporation, the parent company of Orion Pharma, is listed on the Helsinki Stock Exchange.

On another positive note, Lannett was ranked third by Forbes Magazine as one of the 200 Best Small Companies in the country. The competition is based on companies' sales and income performances over the previous five-year period, with an emphasis on the prior twelve months. "We are thrilled to be recognized by Forbes as one of the best small companies. We hope to build on our recent success as we continue to compete in the rapidly-growing generic drug industry," said Bedrosian.

This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Lannett's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Lannett's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration and other regulatory authority approvals, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Lannett's Annual Report on Form 10K for its fiscal year ended June 30, 2004 and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Lannett Company's common stock trades on the American Stock Exchange under the symbol "LCI." For more information, please call Investor Relations at 215/333-9000.

Lannett Company, Inc.

CONTACT: Investor Relations of Lannett Company, Inc., +1-215-333-9000



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES